生物治疗对于预后不良的尤因肉瘤(Ewing’s sarcoma,又称尤文肉瘤)患者具有更好的临床意义，其类型包括基因治疗、免疫治疗、抗血管生成靶向治疗等。尤因肉瘤的基因治疗主要体现在反义核酸技术的应用；免疫治疗主要体现在抗体疗法、T细胞疗法、DC疗法和肿瘤疫苗治疗等方面；抗血管生成治疗主要体现在抑制肿瘤血管的生成，从而抑制肿瘤的生长和迁移。随着研究的深入，发现端粒长度的变化、微粒体谷胱甘肽转移酶1（microsomal glutathione Stransferase 1，MGST1）表达水平、肿瘤转移和多药耐药相关基因的表达以及乳头状瘤病毒结合因子等都有可能成为尤因内瘤预后的判断指标。

Biotherapy is especially beneficial for Ewing’s sarcoma with bad prognosis. The therapy includes gene therapy, immunotherapy, antiangiogenesis therapy, etc.. Gene therapy mainly refers to the application of antisense nucleic acid technique; immunotherapy refers to antibody therapy, T cell therapy, dendritic cell therapy, and tumor vaccine,etc.; and antiangiogenesis therapy refers to inhibition of tumor angiogenesis, thus suppressing tumor growth and metastasis. With the deeper understanding of Ewing’s sarcoma, changes in the telomere length, microsomal glutathione Stransferase 1 (MGST1) expression, the expression of tumor metastasis and multidrug resistance genes, and papillomavirus binding factor might serve as novel predictors for the prognosis of Ewing’s sarcoma.